HC Wainwright reissued their buy rating on shares of ADMA Biologics (NASDAQ:ADMA – Free Report) in a research report report published on Friday morning, Benzinga reports. The firm currently has a $5.00 price objective on the biotechnology company’s stock.
Several other research analysts have also weighed in on ADMA. StockNews.com raised shares of ADMA Biologics from a sell rating to a hold rating in a research note on Friday, November 10th. Raymond James raised their price objective on shares of ADMA Biologics from $5.00 to $6.00 and gave the company a strong-buy rating in a research note on Thursday, August 10th. Cantor Fitzgerald raised their price objective on shares of ADMA Biologics from $5.00 to $6.00 and gave the company an overweight rating in a research note on Thursday, August 10th. Finally, Mizuho raised their price objective on shares of ADMA Biologics from $6.00 to $7.00 in a research note on Thursday, August 10th. One analyst has rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, ADMA Biologics currently has an average rating of Buy and an average price target of $6.00.
ADMA Biologics Price Performance
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). ADMA Biologics had a negative net margin of 9.74% and a negative return on equity of 13.47%. The firm had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $62.13 million. During the same period last year, the business earned ($0.08) earnings per share. ADMA Biologics’s revenue was up 63.7% compared to the same quarter last year. On average, equities analysts predict that ADMA Biologics will post -0.03 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, Director Young Kwon purchased 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was bought at an average price of $3.90 per share, for a total transaction of $97,500.00. Following the completion of the purchase, the director now directly owns 277,401 shares of the company’s stock, valued at $1,081,863.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Jerrold B. Grossman acquired 130,000 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were bought at an average price of $3.71 per share, with a total value of $482,300.00. Following the completion of the acquisition, the director now owns 443,265 shares in the company, valued at $1,644,513.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Young Kwon acquired 25,000 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were bought at an average cost of $3.90 per share, for a total transaction of $97,500.00. Following the acquisition, the director now owns 277,401 shares of the company’s stock, valued at approximately $1,081,863.90. The disclosure for this purchase can be found here. 6.00% of the stock is owned by insiders.
Institutional Trading of ADMA Biologics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tucker Asset Management LLC acquired a new position in shares of ADMA Biologics in the 1st quarter valued at $31,000. Virtu Financial LLC acquired a new position in shares of ADMA Biologics in the 2nd quarter valued at $34,000. Envestnet Asset Management Inc. acquired a new position in shares of ADMA Biologics in the 1st quarter valued at $35,000. Price T Rowe Associates Inc. MD acquired a new position in shares of ADMA Biologics in the 2nd quarter valued at $35,000. Finally, Stephens Consulting LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 73.58% of the company’s stock.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
- Five stocks we like better than ADMA Biologics
- Investing in the Best Airline Stocks
- The most upgraded stocks in November have two things in common
- Investing In Preferred Stock vs. Common Stock
- Monday.com rocked earnings like it’s the weekend
- What is ChatGPT Stock? How to Invest in It
- Plan to own one retailer? Make it this one
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.